1 |
MANCARELLA C, SCOTLANDI K. IGF2BP3 from physiology to cancer: novel discoveries, unsolved issues, and future perspectives[J/OL]. Front Cell Dev. Biol., 2020, 7: 363[2021-10-25]. .
|
2 |
HUANG X, ZHANG H, GUO X, et al.. Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) in cancer[J/OL]. Hematol. Oncol., 2018, 11(1):88[2021-10-25]. .
|
3 |
HUANG H, WENG H, SUN W, et al.. Recognition of RNA N6-methyladenosine by IGF2BP proteins enhances mRNA stability and translation[J]. Nat. Cell Biol., 2018, 20(3): 285-295.
|
4 |
LI Z, PENG Y, LI J, et al.. N6-methyladenosine regulates glycolysis of cancer cells through PDK4[J/OL]. Nat. Commun., 2020, 11(1): 2578[2021-10-25]. .
|
5 |
MÜLLER S, BLEY N, GLAß M, et al.. IGF2BP1 enhances an aggressive tumor cell phenotype by impairing miRNA-directed downregulation of oncogenic factors[J]. Nucl. Acids Res., 2018, 46(12):6285-6303.
|
6 |
GAYNES J A, OTSUNA H, CAMPBELL D S, et al.. The RNA binding protein Igf2bp1 is required for zebrafish RGC axon outgrowth in vivo[J/OL]. PLoS ONE, 2015, 10(9):e0134751[2021-10-25]. .
|
7 |
HUANG T, WANG L, BAI M, et al.. Influence of IGF2BP2, HMG20A, and HNF1B genetic polymorphisms on the susceptibility to Type 2 diabetes mellitus in Chinese Han population [J/OL]. Biosci. Rep., 2020, 40(5): BSR20193955[2021-10-25]. .
|
8 |
WANG Y, LU J H, WU Q N, et al.. LncRNA LINRIS stabilizes IGF2BP2 and promotes the aerobic glycolysis in colorectal cancer[J/OL]. Mol. Cancer, 2019, 18(1):174 [2021-10-25]. .
|
9 |
LIU Z H, LUO S K, WU M Q, et al.. LncRNA GHET1 promotes cervical cancer progression through regulating AKT/mTOR and Wnt/β-catenin signaling pathways[J/OL]. Biosci., Rep., 2020, 40(1): BSR20191265[2021-10-25]. .
|
10 |
MCMULLEN E R, GONZALEZ M E, SKALA S L, et al.. CCN6 regulates IGF2BP2 and HMGA2 signaling in metaplastic carcinomas of the breast[J]. Breast Cancer Res. Treat., 2018, 172(3): 577-586.
|
11 |
CAO J, MU Q, HUANG H. The roles of insulin-like growth factor 2 mRNA-binding protein 2 in cancer and cancer stem cells[J/OL]. Stem Cells Int., 2018, 2018: 4217259[2021-10-25]. .
|
12 |
SCHNEIDER T, HUNG LH, AZIZ M, et al.. Combinatorial recognition of clustered RNA elements by the multidomain RNA-binding protein IMP3[J/OL]. Nat. Commun., 2019, 10(1): 2266[2021-10-25]. .
|
13 |
ENNAJDAOUI H, HOWARD J M, STERNE-WEILER T, et al.. IGF2BP3 modulates the interaction of invasion-associated transcripts with RISC[J]. Cell Rep., 2016, 15(9): 1876-1883.
|
14 |
JØNSON L, CHRISTIANSEN J, HANSEN T V O, et al.. IMP3 RNP safe houses prevent miRNA-directed HMGA2 mRNA decay in cancer and development [J] .Cell Rep., 2014, 7: 539-551.
|
15 |
SCHMIEDEL D, TAI J, YAMIN R, et al.. The RNA binding protein IMP3 facilitates tumor immune escape by downregulating the stress-induced ligands ULPB2 and MICB[J/OL]. Elife, 2016, 5: e13426[2021-10-25]. .
|
16 |
CHEN L, XIE Y, LI X, et al.. Prognostic value of high IMP3 expression in solid tumors: a meta-analysis[J]. Onco. Targets Ther., 2017, 10: 2849-2863.
|
17 |
BURDELSKI C, JAKANI-KARIMI N, JACOBSEN F, et al.. IMP3 overexpression occurs in various important cancer types and is linked to aggressive tumor features: a tissue microarray study on 8,877 human cancers and normal tissues[J]. Oncol. Rep., 2018, 39(1): 3-12.
|
18 |
LIU Y, YU C, WU Y, et al.. CD44+ fibroblasts increases breast cancer cell survival and drug resistance via IGF2BP3-CD44-IGF2 signalling[J]. Cell Mol. Med., 2017, 21(9): 1979-1988.
|
19 |
BAO G, HUANG J, PAN W, et al.. Long noncoding RNA CERS6-AS1 functions as a malignancy promoter in breast cancer by binding to IGF2BP3 to enhance the stability of CERS6 mRNA[J]. Cancer Med., 2020, 9(1): 278-289.
|
20 |
WANG Z, TONG D, HAN C, et al.. Blockade of miR-3614 maturation by IGF2BP3 increases TRIM25 expression and promotes breast cancer cell proliferation[J]. EBioMedicine, 2019, 41: 357-369.
|
21 |
ZHU Q, QU Y, ZHANG Q, et al.. IMP3 is upregulated in primary ovarian mucinous carcinoma and promotes tumor progression[J]. Am. J. Transl. Res., 2017, 9(7): 3387-3398.
|
22 |
LIU H, ZENG Z, AFSHARPAD M, et al.. Overexpression of IGF2BP3 as a potential oncogene in ovarian clear cell carcinoma[J/OL]. Front. Oncol., 2020, 9: 1570[2021-10-25]. .
|
23 |
BI R, SHEN X, ZHANG W, et al.. Clear cell carcinomas of the ovary: a mono-institutional study of 73 cases in China with an analysis of the prognostic significance of clinicopathological parameters and IMP3 expression[J/OL]. Diagn. Pathol., 2016, 11: 17[2021-10-25]. .
|
24 |
郭聪敏.IGF2BP3在卵巢透明细胞癌中的表达及意义[D].大连: 大连医科大学, 硕士学位论文,2010.
|
25 |
HU Y, LI Y, HUANG Y, et al.. METTL3 regulates the malignancy of cervical cancer via post-transcriptional regulation of RAB2B[J/OL]. Eur. J Pharmacol., 2020, 879: 173134[2021-10-25]. .
|
26 |
ZHOU Y, HUANG T, SIU HL, et al.. IGF2BP3 functions as a potential oncogene and is a crucial target of miR-34a in gastric carcinogenesis[J/OL]. Mol. Cancer, 2017, 16(1): 77[2021-10-25]. .
|
27 |
HONG Y, QIN H, LI Y, et al.. FNDC3B circular RNA promotes the migration and invasion of gastric cancer cells via the regulation of E-cadherin and CD44 expression[J]. Cell Physiol., 2019, 234(11): 19895-19910.
|